Purpose. To assess the impact of the COVID-19 pandemic on adherence to oral endocrine therapy in patients diagnosed with breast cancer in the public healthcare system in Catalonia (Spain).Methods. Retrospective cohort study in patients starting endocrine therapy from 2017 to 2021. Adherence was measured during the first year of treatment, and the impact of the pandemic was calculated according to the calendar year and whether the first year of treatment included the peak period of the pandemic in our setting (March–September 2020). Analyses were performed using a chi-square test and multivariable logistic regression, with results stratified by year, age group, and drug type.Results. Mean overall adherence during the first year of treatment was 89.6% from 2017 to 2021. In contrast, the patients who started treatment in 2019 and 2020 and whose treatment included the peak pandemic period presented an adherence of 87.0% and 86.5%, respectively. Young age and tamoxifen or combination therapy were predictors of low adherence. An increase in neoadjuvant therapy was also observed in 2020.Conclusions. The COVID-19 pandemic had only a modest impact on adherence to endocrine therapy (≈3%), despite the enormous disruptions for patients, the healthcare system in general, and cancer care in particular that were occurring in that period.
目的：评估COVID-19大流行对西班牙加泰罗尼亚公共卫生系统中乳腺癌患者口服内分泌治疗依从性的影响。方法：对2017年至2021年开始内分泌治疗的患者进行回顾性队列研究。在治疗第一年测量依从性，并根据日历年以及治疗第一年是否包含本地区大流行高峰期（2020年3月至9月）计算大流行的影响。采用卡方检验和多变量逻辑回归进行分析，结果按年份、年龄组和药物类型分层。结果：2017年至2021年治疗第一年的平均总体依从率为89.6%。相比之下，2019年和2020年开始治疗且治疗期包含大流行高峰期的患者依从率分别为87.0%和86.5%。年轻年龄以及使用他莫昔芬或联合治疗是低依从性的预测因素。2020年还观察到新辅助治疗的增加。结论：尽管COVID-19大流行对患者、整个医疗系统特别是癌症护理造成了巨大干扰，但对内分泌治疗依从性的影响仅为中等程度（约3%）。
肿瘤(癌症)患者之家